Something else? Ask Aunt Vadge – bottom left of your screen!
Your vaginal bacteria seem to play a real part in how vulnerable you are to HIV if you’re exposed.
The link between bacterial vaginosis and HIV is real, but it’s widely misunderstood – so it’s worth getting clear on what it does, and doesn’t, mean.
Women whose vaginal community is dominated by protective Lactobacillus bacteria tend to have a calm, quiet mucosa that’s harder for the virus to take hold in.
Women with a more diverse, Lactobacillus-poor mix – the same pattern we see in bacterial vaginosis (BV) – tend to have more inflammation and more of the exact immune cells HIV likes to infect.1,2
None of this is about blame, and a disrupted microbiome doesn’t doom you to anything. The microbiome is one factor among many, and it only matters in the presence of exposure.
Condoms, PrEP and testing are still the front line, and nothing here changes that. What the research adds is a hopeful angle: the vaginal microbiome is one of the few risk factors you can actually do something about.
Can your vaginal microbiome affect HIV risk?
Yes – the evidence points that way, especially for vaginal exposure.
In a large study of young South African women, those whose vaginal bacteria were diverse and low in Lactobacillus were over four times more likely to acquire HIV than women with a Lactobacillus crispatus-dominant community.1
That’s a big difference, and it held up after accounting for other risk factors.
It’s worth being precise about what this means. The bacteria don’t cause HIV, and a disrupted microbiome on its own can’t give you the virus.
What it appears to do is change the odds when exposure happens – tilting the local environment towards ‘easier to infect’ rather than ‘harder to infect’.
How does vaginal bacteria increase HIV risk?
It comes down to inflammation and target cells. HIV doesn’t infect just any cell – it specifically targets activated immune cells called CD4 T cells, particularly ones carrying a doorway molecule called CCR5.
The more of those activated cells sitting in your vaginal and cervical tissue, the more landing pads the virus has.
Disruptive vaginal bacteria stir up exactly this kind of trouble.
When researchers looked closely at the cervix and vagina, women with diverse, anaerobe-heavy communities had markedly more genital inflammation and more of these activated CD4 cells than women dominated by protective Lactobacillus.2
The immune cells in the tissue effectively sense the disruptive bacteria and call in reinforcements – and those reinforcements are the cells HIV wants.
Protective Lactobacillus, especially L. crispatus, does the opposite.
It keeps the vaginal pH low and acidic, produces lactic acid and other substances that suppress troublemakers, and is associated with a quieter mucosa carrying fewer of those vulnerable cells.2
A calm vagina is, it turns out, a less hospitable one for HIV.
How this changes things in the vagina itself
Your vagina has its own front-line defences, and the microbiome is a huge part of them (we go into this in detail in your vagina’s immune system).
A Lactobacillus-rich community helps maintain an acidic pH, a healthy mucous barrier and a settled immune state. That barrier is part of what stands between an exposure and an infection.
When protective bacteria are crowded out, several things shift at once. The pH rises, the protective lactic acid drops, the mucous layer can thin, and inflammation goes up.
Each of those changes nudges the local conditions in the wrong direction – not just for HIV, but for other infections too, which is why a disrupted microbiome is linked to higher risk across several sexually transmitted infections.
Bacterial vaginosis and HIV: does BV raise the risk?
Bacterial vaginosis and HIV is the link most people actually want to understand, because BV is the most common form of vaginal microbiome disruption.
A meta-analysis pooling 23 studies and more than 30,000 women found that BV was associated with around a 60% higher risk of acquiring HIV.3
That’s consistent with the South African cohort and with the broader pattern across the research.
A later study went a step further and asked which bacteria mattered most.
Tracking women across five African cohorts, researchers found that several specific BV-associated bacteria were linked to higher HIV risk, and the more of them present, the higher the risk climbed.4
So it isn’t only ‘BV: yes or no’ – the particular mix, and how much of it, seems to matter.
None of this means BV ‘leads to’ HIV. Plenty of women have BV and never acquire HIV, and plenty acquire HIV with a perfectly healthy microbiome.
BV is a risk modifier in the presence of exposure – worth treating for many reasons, and one more reason to take a stubborn, recurrent case seriously.
What the headline study actually found
The study that put this on the map followed young, healthy South African women and mapped their vaginal bacteria in detail.1
Women fell roughly into two camps: those dominated by protective Lactobacillus, and those with diverse communities rich in anaerobes such as Prevotella, Sneathia and similar bacteria.
The diverse, Lactobacillus-poor group had the higher HIV risk, and the researchers tied it back to the mechanism – more inflammation, more activated CD4 target cells in the genital tissue.1
They even reproduced the effect in the lab, showing the high-risk bacteria could draw those vulnerable immune cells into the tissue. It’s one of the cleaner demonstrations we have that the microbiome isn’t just a bystander here.
Which bacteria protect, and which don’t
Not all Lactobacillus is equal, and not all ‘good bacteria’ are equally protective. Researchers describe vaginal communities as community state types, and the differences between them are real.6
- L. crispatus-dominant – the most stable and protective state, linked to the calmest mucosa.
- L. gasseri and L. jensenii – also Lactobacillus-led, generally protective.
- L. iners-dominant – Lactobacillus, but a wobblier, less resilient state that tips into disruption more easily.
- Diverse, low-Lactobacillus – the BV-type state linked to inflammation and higher risk.
This is why generic advice to ‘get more good bacteria’ only goes so far. The goal isn’t just any Lactobacillus – it’s a stable, crispatus-led community.
You can read more about what a healthy vaginal microbiome looks like if you want the full picture.
The PrEP twist most people haven’t heard
And this is where the microbiome turns surprisingly practical. Some HIV prevention works by putting an antiretroviral drug directly into the vagina – topical tenofovir gel, for example.
And it turns out your bacteria can interfere with it.
In a study of African women using tenofovir gel, the drug cut HIV incidence by 61% in women with Lactobacillus-dominant communities, but only 18% in women whose communities were dominated by Gardnerella and other anaerobes.5
The reason: Gardnerella vaginalis can rapidly break the drug down before it gets into cells, effectively eating the medication.5
Two important caveats. This was a topical, vaginally applied product – it does not mean oral PrEP (the daily pill most people use) is affected the same way, and oral PrEP remains highly effective.
But it’s a striking reminder that the vaginal environment isn’t a passive bystander to medicine applied locally; it can change how well that medicine works.
Why this matters most for some women – and the representation trap
Most of this research was done with women in sub-Saharan Africa, where both HIV exposure and diverse, low-Lactobacillus vaginal communities are more common.
That’s not a coincidence to gloss over – it’s where the burden of HIV is heaviest, and where this knowledge can do the most good.
It also raises a fairness problem worth naming. A lot of ‘normal vaginal microbiome’ science was built on mostly white, Western women, whose communities skew more Lactobacillus-dominant.
A diverse community isn’t automatically ‘abnormal’ just because it’s less common in the populations researchers happened to study first.
We dig into this in vaginal bacteria around the world – it matters that we don’t pathologise normal variation while still taking genuine risk seriously.
What’s actually modifiable
This is the part we find most useful. You can’t change a lot of HIV risk factors, but the vaginal microbiome is, at least partly, one you can influence.
That makes microbiome care a sensible companion to the standard tools – condoms, PrEP and regular testing – not a replacement for any of them.
The most direct evidence comes from work on restoring L. crispatus after BV treatment.
In a randomised, placebo-controlled trial, women who used a live L. crispatus product after standard antibiotic treatment had significantly less BV recurrence at 12 weeks (30% versus 45% on placebo).7
Restoring protective bacteria, rather than just clearing the disruptive ones, helped the good state actually stick.
This is where functional and naturopathic vaginal care really comes into its own, and it lines up with what the microbiome science is showing.
Rather than only knocking bacteria down with repeated antibiotics, the aim is to rebuild and hold a stable, crispatus-friendly environment – supporting pH, addressing the things that keep disrupting it, and giving protective bacteria a reason to thrive.
It’s slower and more individual than a one-off prescription, but it works with your biology rather than against it.
A reality check, because honesty matters here: simply ‘adding probiotics’ is not proven to lower anyone’s HIV risk, and we shouldn’t pretend otherwise.
The microbiome research is promising, but it’s still early for HIV-specific claims, and the more dramatic interventions aren’t ready – as we explain in why vaginal microbiota transplants aren’t working yet.
Treat microbiome care as part of looking after yourself well, alongside proven prevention, not as a shield on its own.
What this does and doesn’t mean for you
If you’ve had BV, or you know your microbiome runs diverse, there’s no need to panic.
This research is about populations and probabilities, not a verdict on any one person, and most women with a disrupted microbiome will never acquire HIV.
Looking after your vaginal microbiome is still worth doing – for comfort, fewer infections, fertility and pregnancy, and yes, one more small thing in your favour.
If you have ongoing HIV exposure risk, talk to a sexual health service about PrEP and testing, and treat microbiome care as a useful addition rather than the main event.
What to do next
- If HIV exposure is a real possibility for you, see a sexual health or HIV service about PrEP and regular testing – this is the proven front line.
- If you get recurrent BV or you’re not sure what’s going on down there, consider a comprehensive vaginal microbiome test so you know what you’re actually working with.
- If recurrence is your pattern, get to know the drivers of bacterial vaginosis (BV) – that understanding is half the battle.
- For the bigger picture, the community state types and your vagina’s immune system (both linked above) explain how your bacteria shape protection.
Frequently asked questions
Can BV cause HIV?
No. BV doesn’t cause HIV, and you can’t catch HIV from BV itself. What it can do is make you more susceptible if you’re exposed to the virus, by raising inflammation and lowering your protective bacteria.3
Does having BV mean I’ll get HIV?
No. BV is associated with a higher chance of acquiring HIV if you’re exposed, but it doesn’t cause HIV and most women with BV never acquire it.
It’s a risk modifier, not a cause.3
Can improving my vaginal microbiome lower my HIV risk?
It’s plausible, because a Lactobacillus-rich vagina is linked to less inflammation and fewer of the cells HIV targets.1,2
But it hasn’t been proven to reduce HIV risk on its own, so think of microbiome care as a companion to proven prevention, not a substitute.
Does the vaginal microbiome affect PrEP?
For one topical product – vaginal tenofovir gel – yes: certain bacteria can break the drug down and reduce how well it works.5
This finding was specific to a vaginally applied gel and doesn’t mean the standard oral PrEP pill is affected the same way. If you use PrEP, keep taking it as prescribed.
Which bacteria are protective?
Protective vaginal bacteria are mainly Lactobacillus species, with L. crispatus the standout for a stable, calm, acidic environment.6 L. iners is also a Lactobacillus, but it’s a less resilient state that disrupts more easily.
Is this relevant if I’m low risk for HIV?
The HIV-specific angle matters most if you have ongoing exposure risk.
But the same disrupted microbiome is linked to other STIs, pregnancy complications and constant discomfort, so looking after it is worthwhile regardless of your HIV risk.
Will treating my BV reset my risk?
Treating BV is sensible, but antibiotics alone often don’t hold – recurrence is common.
The better target is a stable, protective community afterwards, which is why restoring L. crispatus after treatment shows promise for keeping BV away.7
Should I get my microbiome tested?
If you have recurrent symptoms or you simply want to know your baseline, a comprehensive PCR or NGS test will tell you which bacteria you’re actually carrying – far more useful than guessing.
It’s particularly worthwhile if BV keeps coming back.
The bottom line
Your vaginal microbiome appears to be a real, measurable factor in HIV susceptibility, working through inflammation and the immune cells the virus targets.
A protective, L. crispatus-led community is linked to lower risk; a disrupted, BV-type community to higher.
It’s one factor among many, it only counts in the presence of exposure, and it sits alongside – never instead of – condoms, PrEP and testing.
The encouraging part is that, unlike most HIV risk factors, this is one you can actually work on.
This is general information, not a substitute for personalised medical advice. If you may have been exposed to HIV, or you’re worried about your risk, please see a doctor or a sexual health service.
References
- Gosmann C, Anahtar MN, Handley SA, et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity. 2017;46(1):29–37.
- Anahtar MN, Byrne EH, Doherty KE, et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity. 2015;42(5):965–976.
- Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008;22(12):1493–1501.
- McClelland RS, Lingappa JR, Srinivasan S, et al. Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. Lancet Infect Dis. 2018;18(5):554–564.
- Klatt NR, Cheu R, Birse K, et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science. 2017;356(6341):938–945.
- Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4680–4687.
- Cohen CR, Wierzbicki MR, French AL, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med. 2020;382(20):1906–1915.
